Azitra (AZTR) Asset Writedowns and Impairment (2026)
Azitra (AZTR) reported Asset Writedowns and Impairment of $623532.0 for Q1 2026.
Azitra (AZTR) Asset Writedowns and Impairment (2026) Analysis & Trends
Azitra has reported Asset Writedowns and Impairment for 1 years, with the latest figure at $623532.0 in Q1 2026.
- For the quarter ending Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $623532.0; the trailing twelve-month figure through Mar 2026 stood at $623532.0 (changed N/A YoY), and the FY2024 full-year result was $442793.0, up 26.02% from the prior year.
- Asset Writedowns and Impairment for Q1 2026 stood at $623532.0.
- The five-year high for Asset Writedowns and Impairment was $623532.0 in Q1 2026, with the low at $623532.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Azitra | 20,900.00 | 20,900.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 623,532.00 |
| Mar 31, 2026 | 623,532.00 |